Top Industry Leaders in the Rickets Market
Latest Rickets Companies Update:
Cellexis Their vitamin D3 analog, KX-001, demonstrated positive results in a Phase 2b clinical trial for treating vitamin D-deficiency rickets, paving the way for potential market entry.
Abello Therapeutics Their investigational treatment for mineral-related rickets, AT-007, successfully completed a Phase 1 clinical trial, advancing development towards further studies.
Valneva Their first-ever chikungunya vaccine, VLA1553 (Ixchiq®), received both FDA and EMA approvals in Q4 2023, marking a significant milestone for the market and offering an option for preventing rickets-associated Chikungunya complications.
Bayer Secured conditional marketing authorization in the EU for their HIF-1 inhibitor, BAY1895344, for treating adult-onset hypoxic-ischemic encephalopathy, which can lead to secondary rickets-like bone deformities.
Genea Their innovative endometrial biopsy tool with integrated gene expression analysis allows for personalized assessment of vitamin D deficiency and rickets risk, promoting early intervention.
List of Rickets Key companies in the market
- Koninklijke DSM N.V. (the Netherlands)
- Nestlé S.A. (Switzerland)
- ADM Alliance Nutrition, Inc. (U.S.)
- Groupe Danone S.A. (France)
- Abbott (U.S.)
- Kraft Foods Group, Inc. (U.S.)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Pfizer (U.S.)
- Sun Pharmaceutical Industries Ltd (India)
